A study involving 748 cases of various lymphoma subtypes revealed that CD58 protein expression was downregulated across all B-cell, T-cell, and NK-cell lymphomas; specifically, CD58 downregulation was observed in 14/102 (13.75%) cases of DLBCL, 40/84 (47.6%) cases of small B-cell lymphomas, and 24/29 (82.7%) cases of Follicular Lymphoma. This evidence concerns the gene CD58 and lymphoma.